11 Apr 2024 | Basel | 06:30 PM - 07:30 PM CEST

Digital Self-Care and Injectables: What are the challenges?

About this Meeting

Most patients with long-term conditions are performing some form of self-care as opposed to receiving professional care at hospitals. Injectable treatments have become increasingly common in the self-management of  a wide range of medical conditions. However, these treatments can be complex and challenging for patients to manage, with potential risks of adverse events and suboptimal treatment outcomes. Digital self-care tools offer a promising solution to these challenges, by providing patients with the means to monitor and manage their treatments more effectively. 

In today’s healthcare landscape, pharmaceutical companies have an opportunity to step up to support patients in a more personal way through digital health solutions. The repercussions of subpar self-care management, like therapy drop-offs and low patient engagement, emphasise the urgency to empower individuals in their treatment journeys. 

Join other pharmaceutical executives over dinner and brainstorm how digital health technologies can alleviate pressing patient pain points and support business objectives. With your peers dive deep into the following questions:

  • How does the pharmaceutical industry currently approach strategies for self-care management for injectables? What are the main challenges that digital health strategies can solve? 
  • What data of interest can be captured via digital health during patient self-care and self-injection? Is there an added benefit to having passive adherence data capture? 
  • What are the challenges to real-world usage of digital health solutions supporting injectables?
  • What are the key baseline components for a digital self-care program for injectable treatments? 

Please note: This meeting is part of a three-part series of insights roundtables that HealthXL is hosting in collaboration with Ypsomed. Insights from this roundtable will feed into a white paper that HealthXL and Ypsomed will publish later this year. To sign up to participate in a future session, please get in touch with the HealthXL team.

Participants:

Alexander Klein Founder & CEONedicare
Alexander Klein
Founder & CEONedicare
Annie Boucher International Director, Patient ExperienceNovartis
Annie Boucher
International Director, Patient ExperienceNovartis
Christof Wedemeyer Director Patient Experience Cardio/RenalNOVARTIS
Christof Wedemeyer
Director Patient Experience Cardio/RenalNOVARTIS
Ernst Bos Global Medical DirectorRoche
Ernst Bos
Global Medical DirectorRoche
Evgueni Ivanov Digital Strategy and PortfolioUCB
Evgueni Ivanov
Digital Strategy and PortfolioUCB
Gabriele Tundo PartnerPlexus Ventures
Gabriele Tundo
PartnerPlexus Ventures
Johannes Boshkow Senior Business Development DirectorDawn Health
Johannes Boshkow
Senior Business Development DirectorDawn Health
Julie Carty Head of GrowthHLTH Community
Julie Carty
Head of GrowthHLTH Community
Leonardo Gottlob Global Medical Director at Novo Nordisk
Leonardo Gottlob
Global Medical Director at Novo Nordisk
Matthias Essenpreis CTO Roche DiagnosticsF. Hoffmann-La Roche
Matthias Essenpreis
CTO Roche DiagnosticsF. Hoffmann-La Roche
Mithun Ratnakumar Director Technology Strategy & GovernanceGerresheimer
Mithun Ratnakumar
Director Technology Strategy & GovernanceGerresheimer
Steve Seuntjens PartnerPHS Capital
Steve Seuntjens
PartnerPHS Capital
Susanne Gruber Strategic Healthcare AdvisorIgnited Vision
Susanne Gruber
Strategic Healthcare AdvisorIgnited Vision
Tina Goyal Global Head, Diabetes Business, General MedsSanofi
Tina Goyal
Global Head, Diabetes Business, General MedsSanofi
Valerie Handunge Assoc. Director, Healthcare & Life SciencesVirtusa
Valerie Handunge
Assoc. Director, Healthcare & Life SciencesVirtusa